Home » Relief Therapeutics Will Release Mid/Late-Stage Study Results for COVID-19 Therapy
Relief Therapeutics Will Release Mid/Late-Stage Study Results for COVID-19 Therapy
Relief Therapeutics plans to release topline results this month from a phase 2/3 trial evaluating an intravenous formulation of its COVID-19 treatment, RLF-100 (aviptadil).
The trial, which evaluated aviptadil in critical COVID-19 patients suffering from respiratory failure, is a collaboration between the company and NeuroRx.
NeuroRx has also launched a separate phase 2/3 trial to evaluate whether an inhaled formulation of aviptadil can reduce the likelihood of disease progression to critical COVID-19 with respiratory failure, if administered early.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May